1 |
Kim SH, Cho BL, Shin DW, SS Hwang et al. The effect of asthma clinical guideline for adults on inhaled corticosteroids prescription trend: A quasi-experimental study. J Korean Med Sci 2015;30(8):1048-54.
DOI
|
2 |
Cho SH, Park HW, Rosenbergd DM. The current status of asthma in Korea. J Korean Med Sci 2006;21(2):181-7.
DOI
|
3 |
Scanlon PD, Connett,JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2 Pt 1):381-90.
DOI
|
4 |
Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta (2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;2012(9):CD006829.
|
5 |
Calverley PMA, Anderson JA, Celli B, et al. TORCH investigators, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89.
DOI
|
6 |
Wedzicha JA, Banerji D, Chapman KR et al. IndacaterolGlycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016;374(23):2222-34
DOI
|
7 |
Lee GD, Doh SR, Lee JS et al. Trends and factors in health care utilization of patients with chronic obstructive pulmonary disease in Korea: A nationwide survey from 1990 through 2008. Tuberc Respir Dis 2011;70(4):307-14.
DOI
|
8 |
Health Insurance Review & Assessment Service-Results of adequacy evaluation of chronic obstructive pulmonary disease in 2019 (6th). Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=7209. Accessed July 3, 2022.
|
9 |
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68(11): 1029-36.
DOI
|
10 |
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US), 2014.
|
11 |
Global Initiative for Chronic Obstructive Lung Disease-Global Strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease :2019 Report. Available from https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed July 3, 2022.
|
12 |
Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: A systematic literature review. Int J Chron Obstruct Pulmon Dis 2020;15:417-38.
DOI
|
13 |
Cho KS. Current Status of Chronic Obstructive Pulmonary Disease (COPD) in the Republic of Korea. Public Health Weekly Report 2021;14(16):943-51.
|
14 |
Global Strategy for Prevention, Diagnosis and Management of COPD: 2022 Report. Available from https://goldcopd.org/2022-gold-reports-2/. Accessed July 3, 2022.
|
15 |
An TJ, Yoon HK. Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc 2018;61(9):533-8.
DOI
|
16 |
Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J 2011;20(1):15-22.
|
17 |
Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis 2014;9:277-86.
|
18 |
Park YB, Rhee CK, Yoon HK et al. Revised (2018) COPD clinical practice guideline of the Korean academy of tuberculosis and respiratory disease: A summary. Tuberc Respir Dis (Seoul) 2018;81(4):261-73.
DOI
|
19 |
Denguezli M, Daldoul H, Harrabi I et al. Prevalence and characteristics of undiagnosed COPD in adults 40 years and older - reports from the Tunisian population-based burden of obstructive lung disease study. COPD 2020;17(5):515-22.
DOI
|
20 |
2020 Current Status and Issues of Chronic Diseases. Available from https://kdca.go.kr/gallery.es?mid=a20503020000&bid=0003&act=view&list_no=144928. Accessed July 3, 2022.
|
21 |
Hwang YI, Park YB, Yoo KH et al. Recent trends in the prevalence of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) 2017;80(3):226-9.
DOI
|
22 |
Kim JE. Analysis of drug costs and trends in use of COPD. HIRA Policy Brief 2017;11(1):42-59.
|
23 |
Lee JM, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis 2016;12:27-33.
DOI
|